What Enteron Treats: Main Uses and Benefits

Enteron is commonly used to help with conditions associated with acute or disruptive episodes in the gastrointestinal system, particularly when symptoms are linked to specific bacterial or protozoal activity. The medication may be part of symptomatic management applied in settings that involve temporary physiological imbalance, including certain types of infectious diarrhea, enteritis, Giardiasis, and cholera. The primary benefit is applied in addressing symptoms related to inflammatory or irritative states, which helps ease the overall symptom load and contributes to improved day-to-day comfort.

The medication's scope is also relevant for managing conditions involving specific organisms, and may be part of symptomatic management in protocols for infections that may intensify temporarily, such as certain H. pylori regimens. This use is considered relevant in clinical settings that involve acute or unstable symptom patterns, particularly when managing both bacterial and protozoal pathogens. It assists with coping more steadily when symptoms are more noticeable and offers symptomatic relief that helps patients manage difficult episodes.

---

Quick Facts: Therapeutic Use

Property	Description
Symptom Focus	Helps address symptoms that create noticeable physiological strain, such as acute diarrheal patterns and abdominal discomfort.
Condition Context	Applied in conditions involving episodic or fluctuating manifestations linked to bacterial and protozoal infection.
Therapeutic Benefit	Supports patients during difficult episodes by easing distress and contributing to improved day-to-day comfort.

Regulatory References

1. National Cancer Institute Drug Dictionary overview

Official Population Eligibility for Enteron

This section outlines the official, label-based rules governing who can and cannot use the medicine containing Furazolidone (Enteron), as documented in governmental regulatory sources.

Category	Status	Details from Regulatory Labeling
Populations for whom use is allowed	Established	Adults and children 1 month of age and over.
Populations for whom use is contraindicated	Absolute Exclusion	Individuals with known Hypersensitivity to Furazolidone or other Nitrofuran derivatives.
Age-related eligibility rules	Minimum Age Restriction	Infants under 1 month of age are not recommended to receive the medicine due to the risk of hemolytic anemia from immature enzyme systems.
Condition-specific eligibility rules	Conditional/Caution	Use requires caution in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to the potential for mild, reversible hemolytic anemia.
Pregnancy and lactation eligibility	Safety Not Established	Use during pregnancy and lactation is generally not recommended, as official safety and concentration data are not established.
Eligibility-related restrictions	Prohibited Exposure	Ingestion of alcohol or alcohol-containing preparations is prohibited during therapy and for at least four days afterward, due to the officially documented risk of a severe disulfiram-like reaction.

The official eligibility profile is defined by these absolute exclusions and specific requirements. Regulatory documents emphasize that use in the elderly is not specifically studied or compared, and that the concomitant exposure to substances like tyramine-containing foods must be avoided.

Interactions with other medicines and products

Enteron (Furazolidone) has an official interaction profile defined by its function as a Monoamine Oxidase Inhibitor (MAOI), resulting in several strict regulatory restrictions.

---

Contraindicated Combinations and Substances

Co-administration is formally contraindicated with other MAO Inhibitors. The regulatory label also prohibits use alongside Indirectly-Acting Sympathomimetic Amines (e.g., certain nasal decongestants, Ephedrine, Phenylephrine, or anorectics) due to the risk of severe Hypertensive Crisis.

---

Dietary and Substance Restrictions

Substance	Restriction/Caution	Timing Separation Requirement
Alcohol/Ethanol	Contraindicated; risk of a Disulfiram-like reaction.	Avoid during therapy and for 4 days after stopping medication.
Tyramine-Containing Foods	Contraindicated; risk of Hypertensive Crisis.	Avoid during therapy and for at least 2 weeks after stopping medication.
Caffeine (Large Amounts)	Should be avoided.	No specific timing separation documented.
Herbal Supplements	Caution is advised; documented interactions with Bitter Orange and Ginseng.	No specific timing separation documented.

---

Population-Specific Notes

The regulatory information notes caution regarding specific populations: use is not recommended for infants under 1 month of age. Furthermore, patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency may experience mild, reversible intravascular hemolysis.

Pathogen-Targeted Activation and Genetic Damage

The drug is fundamentally a prodrug that requires activation by specific nitroreductase enzymes found within susceptible pathogens. Once reduced, the molecule creates highly reactive intermediates that cause irreversible damage by forming covalent bonds with the microbe's DNA and essential macromolecules. This core mechanism dictates that the drug is activated only where the pathogen's unique enzyme system exists.

Disruption of Microbial Energy and Metabolic Pathways

The activated drug further operates by directly inhibiting critical enzyme systems essential for metabolic function within the pathogen, including those involved in the Krebs cycle and cellular respiration. This mechanistic domain simultaneously depletes the organism's access to energy and key metabolic precursors, which results in a multi-faceted failure that leads to rapid cessation of proliferation and metabolic shutdown.

Secondary Constraint via Host Monoamine Oxidase (MAO) Inhibition

The molecule exerts a secondary, non-antimicrobial action by inhibiting the host's Monoamine Oxidase (MAO) enzyme, primarily in the gastrointestinal tract. This action reduces the host's ability to break down biological amines, thereby reducing the systemic rate of amine catabolism. This physiological consequence acts as an intrinsic constraint on the drug's overall profile.

Administration Guidelines

The administration of Enteron (Furazolidone) follows a structured protocol for use exclusively via the oral route. This medicine is typically available in a 100 mg tablet form and as an oral suspension.

---

Dosing and Frequency

The standard adult regimen involves taking a 100 mg dose four times a day (QID), with administrations spaced approximately six hours apart. The maximum daily dose for short-term use is 400 mg.

Usage Constraint	Detail
Dosing Frequency	Four times a day (QID)
Adult Dose	100 mg per dose
Administration Timing	May be taken with food
Missed Dose Rule	Take as soon as possible, or skip if near the next dose; do not double doses

---

Course Duration and Adjustments

The duration of use is defined by established treatment parameters: treatment typically spans 5 to 7 days for certain bacterial episodes and 7 to 10 days for Giardiasis. Completion of the full prescribed course is required.

Special Population Constraints: Use is not recommended for infants under 1 month of age. For children 1 month and older, a weight-based dosing calculation is necessary, involving an approximate dose of 1.25 mg/kg of body weight per dose, also administered four times daily.

Suspension Preparation: When using the oral suspension, the container must be shaken vigorously before each dose, which must be accurately measured using a calibrated device.

These instructions define the precise operational steps for using the medication, structuring the protocol by route, frequency, and mandatory course length.

Research Evidence / Overview of Studies for Enteron

Evidence for Use in Acute Infectious Diarrhea

Research examining Enteron (furazolidone) has been conducted in the context of acute diarrhea, focusing on conditions associated with susceptible bacterial and protozoal pathogens. This evidence primarily comes from older short-term Randomized Controlled Trials (RCTs) and observational studies.

Studies were conducted in populations that included adults and children, often studied in regions with a high prevalence of infectious diarrhea. Findings describe patterns observed in the studies, including measurements of the time interval to symptom change or resolution. Certainty remains low-to-moderate, as assessed by systematic reviews, due to the age and variability of the primary research; findings were noted to be heterogeneous (varied) across some reported trials.

---

Evidence for Use in Giardiasis

The evidence base for Enteron in studies examining Giardiasis (Giardia lamblia infection), a protozoal condition, includes numerous comparative RCTs and systematic reviews. Studies measured the parasitological outcome (absence of the parasite) through follow-up stool testing several weeks after the study period. Studies reported measurements for both the parasitological outcome and clinical outcomes (symptom resolution) when Enteron was evaluated over defined study periods, typically 7 to 10 days. This evidence contributes to the broader research landscape examining options for this condition.

What remains uncertain is the long-term characterization of outcomes beyond the short-term clearance confirmation. Additionally, there are limited data available for the study of Giardiasis in certain specific patient subgroups, such as pregnant populations.

---

Research Gaps and Uncertainties

Enteron has also been studied as one specific agent within multi-drug regimens for H. pylori infection, measuring the eradication rate in affected adults. However, because Enteron is studied only as one component of a multi-drug approach, its specific contribution to the measured outcome of the regimen is not independently characterized. Furthermore, data for certain groups remain insufficient, and its use outside of specific regional protocols is not fully established. The findings describe group patterns, not personal outcomes, and evidence remains limited regarding long-term functional status.

Key Studies & References

1. Drug Dictionary: Furazolidone
2. Comparative effectiveness of treatments for giardiasis: a systematic review and network meta-analysis
3. Effectiveness of furazolidone-based quadruple therapy for H. pylori infection: a systematic review and meta-analysis

How to Store and Dispose of Enteron

Enteron (Furazolidone) must be stored under specific environmental constraints to maintain its stability, as defined in official regulatory labeling.

Official Storage Conditions

Condition	Requirement
Temperature	Store at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Protection	Protect from moisture and avoid excessive heat.
Prohibition	The product, especially the oral suspension, must not be frozen.
Container	Keep the medication in the original, tightly closed container.
Stability	The reconstituted Oral Suspension must be discarded after 14 days.

Disposal and Safety

Unused or expired Enteron must be kept out of the sight and reach of children. Disposal should follow local regulations, ideally by utilizing a formal medicine take-back program. To protect the environment, the product should not be disposed of via wastewater or thrown into general household trash unless prepared according to official guidance.